Abstract
Respiratory syncytial virus (RSV) is a common virus that infects people of all ages and causes cold-like symptoms in most cases. However, more serious infections occur in the younger and older extremities of the population causing severe lung infections such as bronchiolitis and pneumonia. The current standard of care is mostly limited to supportive treatment, although prophylaxis by passive immunization with the humanized monoclonal antibody palivizumab and therapeutic intervention with aerosolized ribavirin are available. Unfortunately, administration of palivizumab is restricted to at-risk infants up to the age of two and is associated with high cost, while ribavirin treatment is hindered by questionable efficacy and safety reasons. Consequently, the development of novel specific RSV antiviral drugs is needed to help decrease RSV-related morbidity and mortality. We describe here a fluorescence-based high-throughput screening assay to discover RSV inhibitors which is based on the infection of HeLa cells with a recombinant RSV strain that contains an enhanced green fluorescent protein coding sequence in its viral genome.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Krusat T, Streckert HJ (1997) Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch Virol 142:1247–1254
Lamb RA (1993) Paramyxovirus fusion: a hypothesis for changes. Virology 197:1–11
Martin AJ, Gardner PS, McQuillin J (1978) Epidemiology of respiratory viral infection among paediatric inpatients over a six-year period in north-east England. Lancet 2:1035–1038
Weber MW, Mulholland EK, Greenwood BM (1998) Respiratory syncytial virus infection in tropical and developing countries. Trop Med Int Health 268–280
Nair H, Nokes DJ, Gessner BD et al (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545–1555
Falsey AR, Hennessey PA, Formica MA et al (2005) Respiratory syncytial virus infection in elderly and high-risk adults. New England J Medicine 352:1749–1759
Collins PL, Crowe JE Jr (2007) Respiratory syncytial virus and metapneumovirus. In: Knipe DM, Howley PM et al (eds) Fields virology. Lippincott Williams & Wilkins, Philadelphia, PA, pp 1601–1646
Hallak LK, Spillmann D, Collins PL, Peeples ME (2000) Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 74:10508–10513
Hallak LK, Collins PL, Knudson W, Peeples ME (2000) Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology 271:264–275
Cianci C, Genovesi EV, Lamb L et al (2004) Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother 48:2448–2454
Bonfanti JF, Meyer C, Doublet F et al (2008) Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Medicinal Chem 51:875–896
Ventre K, Randolph AG (2007) Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 1:CD000181
Chapman J, Abbott E, Alber DG et al (2007) RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 51:3346–3353
Gupta CK, Leszczynski J, Gupta RK, Siber GR (1996) Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 14:1417–1420
Acknowledgments
The authors wish to thank Koen Van Acker and Pascale Holemans who assisted in the development of the original RSV fluorescence-based assay in a 96-well plate format.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kwanten, L., De Clerck, B., Roymans, D. (2013). A Fluorescence-Based High-Throughput Antiviral Compound Screening Assay Against Respiratory Syncytial Virus. In: Gong, E. (eds) Antiviral Methods and Protocols. Methods in Molecular Biology, vol 1030. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-484-5_26
Download citation
DOI: https://doi.org/10.1007/978-1-62703-484-5_26
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-483-8
Online ISBN: 978-1-62703-484-5
eBook Packages: Springer Protocols